Modulation of alternative MDM2 splicing
View Patent ↗Compositions and methods for treating cancer in a subject in need thereof are described that includes administering a therapeutically effective amount of an oligonucleotide that inhibits the binding of splicing regulator SRSF1 or SRSF2 to MDM2 exon 4 or 11.
1. A method of treating cancer in a subject in need thereof, comprising administering a therapeutically effective amount of an antisense oligonucleotide that inhibits the binding of splicing regulator SRSF1 or SRSF2 to MDM2 exon 11, wherein the antisense oligonucleotide includes from 10 to 30 nucleotides, and a portion of the antisense oligonucleotide is complementary to the nucleotide sequence AGTTACTG or AGATCCTG, wherein the cancer exhibits elevated MDM2-ALT1 and SRSF1 expression.
2. The method of claim 1 , wherein the splicing regulator is SRSF1.
3. The method of claim 2 , wherein the oligonucleotide is a sense oligonucleotide, and a portion of the sense oligonucleotide comprises the nucleotide sequence GGCAGGGGA.
4. The method of claim 2 , wherein the oligonucleotide is SEQ ID NO: 6 or SEQ ID NO: 7.
5. The method of claim 2 , wherein the cancer comprises mutant tumor suppressor protein p53.
6. The method of claim 1 , wherein the splicing regulator is SRSF2.
7. The method of claim 6 , wherein the cancer comprises a wild-type form of tumor suppressor protein p53.
8. The method of claim 6 , wherein the oligonucleotide is SEQ ID NO: 3, SEQ ID NO: 4, or SEQ ID NO: 5.
9. The method of claim 1 , wherein the oligonucleotide is a siRNA.
10. The method of claim 1 , wherein the oligonucleotide is a 2′-O-alkyl antisense oligonucleotide.
11. The method of claim 1 , wherein the subject is also undergoing one or more cancer therapies selected from the group consisting of surgery, chemotherapy, radiotherapy, thermotherapy, immunotherapy, hormone therapy, or laser therapy.